CHF718 pMDI with HFA-134a

Phase 2Small molecule

Chiesi Farmaceutici S.p.A.

CHF718 pMDI with HFA-134a is one of 21 small molecule programs targeting Asthma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

AsthmaActive, not recruiting

AsthmaPhase 2

Active, not recruiting

Competition

Competitive Landscape

1050 competitors in Asthma

#DrugCompanyPhaseTrials

Cinqair

Teva

Preclinical

13 2

Dupixent

AAzienda U.S.L. 1 di Massa e Carrara

Preclinical

30 3

Atrovent

Boehringer Ingelheim

Preclinical

5 4

Arcoxia

Symbicort

6 6

Atrovent

Boehringer Ingelheim

Preclinical

2 7

Aciphex

Akero Therapeutics

Preclinical

2 8

Decadron

QQuince Therapeutics S.p.A.

Preclinical

1 9

Tylenol

KKenvue Brands

Preclinical

1 10

CHF718 pMDI with HFA-134a

Chiesi Farmaceutici S.p.A.

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 2Recruiting

Asthma

NCT07301736

Clinical

Trials by Indication[1]

Asthma1 trial

A Phase II Multinational, Multicentre, Double-blind, Randomised, Active-controlled, 3-way Cross-over Study to Evaluate the Therapeutic Equivalence of CHF5993 pMDI 100/6/12.5 µg HFA-152a Versus CHF5993 pMDI 100/6/12.5 µg HFA-134a in Subjects With Mild to Moderate Asthma

Recruiting· Chiesi Farmaceutici S.p.A. logo

Chiesi Farmaceutici S.p.A.·Phase 2·NCT07301736·780 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for CHF718 pMDI with HFA-134a. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CHF718 pMDI with HFA-134a compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CHF718 pMDI with HFA-134a. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Chiesi Farmaceutici S.p.A. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Chiesi Farmaceutici S.p.A.

CHF718 pMDI with HFA-134a

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Asthma1 trial

References

Drug Info

Quick Facts

Related News